Vanda Pharmaceuticals (VNDA) Revenue & Revenue Breakdown
Vanda Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$192.64M
Latest Revenue (Q)
$50.47M
Main Segment (Y)
Hetlioz
Vanda Pharmaceuticals Revenue by Period
Vanda Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $192.64M | -24.27% |
| 2022-12-31 | $254.38M | -5.32% |
| 2021-12-31 | $268.68M | 8.27% |
| 2020-12-31 | $248.17M | 9.23% |
| 2019-12-31 | $227.19M | 17.64% |
| 2018-12-31 | $193.12M | 16.98% |
| 2017-12-31 | $165.08M | 13.06% |
| 2016-12-31 | $146.02M | 32.83% |
| 2015-12-31 | $109.92M | 119.16% |
| 2014-12-31 | $50.16M | 48.05% |
| 2013-12-31 | $33.88M | 3.52% |
| 2012-12-31 | $32.73M | 4.66% |
| 2011-12-31 | $31.27M | -11.22% |
| 2010-12-31 | $35.22M | 674.45% |
| 2009-12-31 | $4.55M | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2007-12-31 | - | 100.00% |
| 2006-12-31 | - | 100.00% |
| 2005-12-31 | - | -100.00% |
| 2004-12-31 | $33.98K | - |
Vanda Pharmaceuticals generated $192.64M in revenue during NA 2023, up -24.27% compared to the previous quarter, and up 99.75% compared to the same period a year ago.
Vanda Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $50.47M | 6.35% |
| 2024-03-31 | $47.46M | 4.84% |
| 2023-12-31 | $45.27M | 16.63% |
| 2023-09-30 | $38.81M | -15.72% |
| 2023-06-30 | $46.06M | -26.31% |
| 2023-03-31 | $62.50M | -3.08% |
| 2022-12-31 | $64.48M | -1.28% |
| 2022-09-30 | $65.32M | 1.44% |
| 2022-06-30 | $64.39M | 6.97% |
| 2022-03-31 | $60.19M | -11.51% |
| 2021-12-31 | $68.02M | -2.96% |
| 2021-09-30 | $70.09M | 3.23% |
| 2021-06-30 | $67.90M | 8.35% |
| 2021-03-31 | $62.67M | -7.37% |
| 2020-12-31 | $67.65M | 12.18% |
| 2020-09-30 | $60.31M | -3.05% |
| 2020-06-30 | $62.21M | 7.25% |
| 2020-03-31 | $58.00M | -4.81% |
| 2019-12-31 | $60.93M | 2.43% |
| 2019-09-30 | $59.48M | 0.72% |
| 2019-06-30 | $59.06M | 23.78% |
| 2019-03-31 | $47.71M | -10.05% |
| 2018-12-31 | $53.04M | 7.95% |
| 2018-09-30 | $49.13M | 3.77% |
| 2018-06-30 | $47.35M | 8.62% |
| 2018-03-31 | $43.59M | -1.54% |
| 2017-12-31 | $44.28M | 7.11% |
| 2017-09-30 | $41.34M | -1.71% |
| 2017-06-30 | $42.06M | 12.40% |
| 2017-03-31 | $37.41M | -2.17% |
| 2016-12-31 | $38.24M | -0.62% |
| 2016-09-30 | $38.48M | 6.81% |
| 2016-06-30 | $36.03M | 8.32% |
| 2016-03-31 | $33.26M | 4.44% |
| 2015-12-31 | $31.85M | 12.37% |
| 2015-09-30 | $28.34M | 2.76% |
| 2015-06-30 | $27.58M | 24.52% |
| 2015-03-31 | $22.15M | 44.12% |
| 2014-12-31 | $15.37M | 3.97% |
| 2014-09-30 | $14.78M | 36.09% |
| 2014-06-30 | $10.86M | 18.80% |
| 2014-03-31 | $9.14M | 4.10% |
| 2013-12-31 | $8.78M | 0.85% |
| 2013-09-30 | $8.71M | 4.69% |
| 2013-06-30 | $8.32M | 3.11% |
| 2013-03-31 | $8.07M | 1.87% |
| 2012-12-31 | $7.92M | -4.44% |
| 2012-09-30 | $8.29M | -1.07% |
| 2012-06-30 | $8.38M | 2.91% |
| 2012-03-31 | $8.14M | -2.74% |
| 2011-12-31 | $8.37M | 5.03% |
| 2011-09-30 | $7.97M | 7.25% |
| 2011-06-30 | $7.43M | -0.95% |
| 2011-03-31 | $7.50M | -3.24% |
| 2010-12-31 | $7.75M | 6.98% |
| 2010-09-30 | $7.25M | -12.59% |
| 2010-06-30 | $8.29M | -33.26% |
| 2010-03-31 | $12.42M | 173.12% |
| 2009-12-31 | $4.55M | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | - |
Vanda Pharmaceuticals generated $50.47M in revenue during Q2 2024, up 6.35% compared to the previous quarter, and up 80.76% compared to the same period a year ago.
Vanda Pharmaceuticals Revenue Breakdown
Vanda Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Hetlioz | $100.17M | $159.66M | $173.54M | $160.69M | $142.98M |
| Fanapt | $90.87M | $94.73M | $95.15M | $87.48M | $84.21M |
Latest
Vanda Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Hetlioz (52.43%), and Fanapt (47.57%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hetlioz | $17.87M | $18.71M | $20.05M | $21.07M | $17.50M | $21.98M | $39.62M | $40.10M | $41.34M | $41.19M | $37.03M | $44.07M | $45.62M | $44.51M | $39.34M | $44.17M | $39.62M | $41.56M | $35.34M | $38.60M |
| Fanapt | $23.92M | $23.15M | $20.58M | $22.60M | $21.32M | $24.08M | $22.88M | $24.38M | $23.98M | $23.20M | $23.16M | $23.95M | $24.48M | $23.39M | $23.33M | $23.48M | $20.69M | $20.65M | $22.66M | $22.33M |
Latest
Vanda Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Fanapt (57.24%), and Hetlioz (42.76%).
Vanda Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
| TECH | Bio-Techne | $1.16B | $289.46M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| VNDA | Vanda Pharmaceuticals | $192.64M | $50.47M |
| RCUS | Arcus Biosciences | $117.00M | $48.00M |
| TSVT | 2seventy bio | $100.39M | $13.53M |
| RLAY | Relay Therapeutics | $25.55M | - |
| LQDA | Liquidia | $17.49M | $4.45M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| CYTK | Cytokinetics | $7.53M | $463.00K |
| KZR | Kezar Life Sciences | $7.00M | - |
| PHAT | Phathom Pharmaceuticals | $682.00K | $16.35M |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| CNTB | Connect Biopharma | - | - |
| TIL | Instil Bio | - | - |
| GRPH | LENZ Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| ANNX | Annexon | - | - |
| NLTX | Neurogene | - | - |
| NUVB | Nuvation Bio | - | $727.00K |